MTAP deletion is one of the most common genetic losses in human cancer, found in roughly one in ten tumors across all types, and it has rapidly emerged as both a prognostic biomarker and a druggable vulnerability. The gene encodes an enzyme that recycles a metabolic byproduct, and when it disappears, cancer cells accumulate a substance that rewires their internal chemistry in ways that can be exploited by a new generation of targeted therapies. Several drug candidates designed around this vulnerability are now in clinical trials, and the field has expanded to include immune-related consequences that could reshape how immunotherapy is paired with metabolic targeting.
What MTAP Does in Healthy Cells
MTAP stands for methylthioadenosine phosphorylase, an enzyme that breaks down a molecule called methylthioadenosine, or MTA. MTA is a natural byproduct of polyamine biosynthesis, a metabolic process involved in cell growth and division.1PubMed Central. Methylthioadenosine phosphorylase deficiency in tumors: A compelling therapeutic target By cleaving MTA, MTAP feeds its breakdown products back into the methionine salvage pathway, helping the cell recycle methionine and adenine rather than manufacturing them from scratch. In healthy tissue, this keeps MTA levels low and the methionine cycle running efficiently. When cancer cells lose both copies of the MTAP gene, that recycling stops, and MTA begins to pile up both inside the cell and in the surrounding tissue.
Why MTAP Gets Deleted So Often in Cancer
The MTAP gene sits on chromosome 9p21, right next to a cluster of well-known tumor suppressor genes, including CDKN2A (which encodes the p16 protein). Deletions targeting CDKN2A are among the most frequent genetic events in cancer, and because MTAP is a close neighbor, it often gets swept away in the same deletion. This is collateral damage: the tumor is “trying” to lose the growth brakes encoded by CDKN2A, and MTAP disappears as a passenger. The practical result is that MTAP loss is extremely common but varies widely by tumor type.
A systematic review of MTAP deletions across solid and blood cancers found that prevalence ranged from low single digits in some tumor types to over half of all cases in others, with glioblastoma at the high end (roughly 26% to 60%) and gastric cancer at the low end (about 4% to 14%).2PubMed. A systematic literature review of MTAP deletions in solid and hematologic Cancers A large real-world analysis of nearly 11,000 patients put the overall rate of homozygous MTAP deletion at about 9.4%, with glioblastoma highest at 58% and mesothelioma at around 41%.3PubMed. Clinical Presentation of MTAP Deletions in Real-World Settings: Lessons for the Clinical Development of Novel Targeted Therapies A separate pan-cancer study using data from over 51,000 patients in Japan found MTAP deletion in 9.6% overall, with particularly high rates in pleural tumors (33%), bladder and urinary tract cancers (24%), brain tumors (19%), and pancreatic cancer (18%).4PubMed Central. Pan-clinical and molecular landscape of MTAP deletion in nationwide and international comprehensive genomic data Breast, prostate, and colorectal cancers had some of the lowest rates.
In blood cancers, MTAP loss has been documented for decades, especially in T-cell acute lymphoblastic leukemia (T-ALL), where the deletion rate in one study reached about 39% among patients at diagnosis.5PubMed. Detection of methylthioadenosine phosphorylase (MTAP) and p16 gene deletion in T cell acute lymphoblastic leukemia by real-time quantitative PCR assay The frequency tends to increase at relapse, suggesting that MTAP-deleted clones may have a survival advantage under treatment pressure.
What Happens When MTA Accumulates
The metabolic consequences of MTAP loss are central to why it matters therapeutically. When MTAP is gone, MTA accumulates to levels far above normal. In one large screen of 249 cancer cell lines, MTA showed the single largest abundance increase of any detected metabolite in MTAP-deleted cells, and these cells also secreted MTA into the surrounding medium.6Cell Reports. Methylthioadenosine Phosphorylase Deletion in Cancer This excess MTA doesn’t just sit there. It acts as a natural inhibitor of an enzyme called PRMT5, which adds methyl tags to proteins and plays an important role in gene regulation and cell survival. MTA’s inhibitory effect on PRMT5 is remarkably specific: its potency against PRMT5 was found to be more than 20-fold greater than against any other methyltransferase tested.6Cell Reports. Methylthioadenosine Phosphorylase Deletion in Cancer
The result is that MTAP-deleted cancer cells already operate with partially suppressed PRMT5 activity, a state researchers describe as “hypomorphic.”7PubMed. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5 Normal cells with intact MTAP keep MTA low, so their PRMT5 runs at full capacity. MTAP-deleted tumor cells are living on the edge of PRMT5 insufficiency. Push PRMT5 activity down a little further with a drug, and normal cells can tolerate the hit while the tumor cells cannot. This concept, called synthetic lethality, is the foundation of several drug programs now in development.
The PRMT5 and MAT2A Drug Targets
Two main therapeutic targets have emerged from this biology. The first is PRMT5 itself. Because MTA is already occupying part of the PRMT5 binding site in MTAP-deleted cells, researchers designed a new class of drugs called MTA-cooperative PRMT5 inhibitors. These compounds are engineered to bind PRMT5 specifically when MTA is present, meaning they preferentially inhibit PRMT5 in tumor cells that lack MTAP while leaving normal cells relatively unaffected. An optimized compound called AM-9934, identified through DNA-encoded library screens, selectively inhibited PRMT5 in MTAP-deleted cells and tumors while sparing their MTAP-expressing counterparts.8PubMed Central. MTA-cooperative PRMT5 inhibitors from cofactor-directed DNA-encoded library screens Other groups have reported orally bioavailable MTA-cooperative PRMT5 inhibitors with robust tumor suppression in animal models of MTAP-deleted lung cancer.9PubMed. Discovery of Potent, Highly Selective, and Orally Bioavailable MTA Cooperative PRMT5 Inhibitors with Robust In Vivo Antitumor Activity
The second target is MAT2A, the enzyme that converts methionine into S-adenosylmethionine (SAM), the universal methyl donor cells use for countless biochemical reactions. In the original functional genomics screen that mapped MTAP-related vulnerabilities, MAT2A was the top-scoring synthetic lethal hit.6Cell Reports. Methylthioadenosine Phosphorylase Deletion in Cancer Blocking MAT2A lowers SAM levels, which in turn starves PRMT5 of the methyl groups it needs. MTAP-deleted cells, which are already running low on PRMT5 activity, are hit especially hard. Potent MAT2A inhibitors have shown antiproliferative activity in MTAP-deleted cancer cells and tumor models.10Cancer Cell. MTAP Deletion: Its Role as a Biomarker and Cancer Target
There is also a related angle involving type I protein arginine methyltransferases (type I PRMTs). One study found that MTAP-deficient cell lines from lymphoma, melanoma, and pancreatic cancer were at least six-fold more sensitive to a type I PRMT inhibitor than their wild-type counterparts, with sensitivity increasing further over longer exposure periods.11Cancer Cell. Discovery of a Potent and Reversible Type I PRMT Inhibitor that Exhibits Robust Anti-tumor Activity and Synergizes with PRMT5 Inhibition This opens the door to combination strategies that attack the arginine methylation machinery from multiple angles.
How MTAP Loss Is Detected
Identifying which patients have MTAP-deleted tumors is a practical challenge with real consequences for clinical trial enrollment and, eventually, for treatment decisions. Three main methods are in use, each with strengths and limitations.
Next-generation sequencing (NGS), often performed as part of comprehensive genomic profiling, can detect MTAP gene deletions at the DNA level. It is increasingly standard in oncology workups, but NGS struggles with certain edge cases. When tumor content in a biopsy is low (below roughly 30%), the algorithms can fail to accurately call a homozygous deletion. And some genomic scenarios, like a non-diploid genome with multiple copy states, can lead to incorrect calls.12Laboratory Investigation. A Complementary Role for Immunohistochemistry and NGS for Detection of MTAP Gene Deletion in Patients with Non-Small Cell Lung Cancer
Immunohistochemistry (IHC) offers a complementary approach by staining tumor tissue for the MTAP protein itself. If the protein is absent, the gene is likely deleted. The choice of antibody matters: a study comparing IHC to molecular methods in pleural mesothelioma found that one antibody (clone 1813) achieved 96% sensitivity, 86% specificity, and 93% overall accuracy for detecting homozygous 9p21 deletion, while a different clone was often limited by equivocal results.13PubMed Central. Comparison of Immunohistochemistry, Next-generation Sequencing and Fluorescence In Situ Hybridization for Detection of MTAP Loss in Pleural Mesothelioma A newer antibody (2G4) demonstrated 100% sensitivity and 92.5% specificity when evaluated against FISH as the reference standard, and proved especially useful for resolving cases that sequencing classified as ambiguous.14Modern Pathology. Immunohistochemistry Resolves Indeterminate MTAP Deletion Calls from Exome Sequencing: A Pan-Cancer Concordance Study In a non-small cell lung cancer cohort, NGS and IHC agreed in about 94% of cases, though each method caught a handful of deletions the other missed.12Laboratory Investigation. A Complementary Role for Immunohistochemistry and NGS for Detection of MTAP Gene Deletion in Patients with Non-Small Cell Lung Cancer The takeaway for pathology labs is that combining IHC and molecular testing catches more cases than either alone.
For patients where tissue is unavailable or difficult to biopsy, liquid biopsy is gaining traction. A methylation-based algorithm applied to circulating tumor DNA achieved an area under the curve of 0.91 for detecting MTAP deletion across multiple cancer types, resolving copy-number loss even at tumor fractions as low as 1%.15Cancer Research. A Tumor-specific, methylation-based algorithm to identify MTAP gene deletions via tissue-free circulating tumor DNA A separate study confirmed that MTAP loss can be detected in blood-based circulating tumor DNA across different non-small cell lung cancer subtypes when sufficient tumor fraction is present, offering a practical alternative when rapid results or repeat testing is needed.16Cancer Research. Abstract 1131: A novel detection strategy for an emerging biomarker: MTAP loss detection with circulating tumor DNA (ctDNA)
MTAP Loss as a Prognostic Marker
Beyond its role as a drug target, MTAP deletion carries prognostic weight. In metastatic urothelial cancer, MTAP-deficient patients had a median overall survival of about 12 months compared to about 20 months for MTAP-intact patients, an adjusted hazard ratio of roughly 1.9.17PubMed Central. Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer MTAP-deficient patients also had a higher rate of visceral metastases, pointing to a more aggressive disease biology. In cholangiocarcinoma (bile duct cancer), the association was even starker: MTAP loss was linked to an adjusted hazard ratio of nearly 4.0 for death.18PubMed Central. Prognostic Role of MTAP Loss in Cholangiocarcinoma These findings suggest that MTAP status may eventually join other genomic markers used to stratify patients and guide treatment intensity, especially as MTAP-targeted therapies become available and clinicians need to identify who stands to benefit.
How MTAP Loss Sabotages the Immune System
One of the more consequential discoveries in this area is that MTAP deletion doesn’t just create a vulnerability inside the tumor cell — it also poisons the immune environment around it. MTA, the metabolite that accumulates when MTAP is missing, leaks out of tumor cells and suppresses the immune cells that are supposed to attack the cancer. It impairs T cell function through at least two routes: by inhibiting PRMT5 activity in T cells and by activating adenosine receptors that dampen immune activation.19PubMed Central. Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistance
The damage extends beyond T cells. MTA also interferes with dendritic cells, the immune system’s alarm-raisers. Monocytes matured in the presence of MTA developed into dendritic cells with a more immature-like profile: they produced less of the cytokine IL-12, expressed lower levels of co-stimulatory molecules needed to activate T cells, and retained markers of undifferentiated monocytes. The net effect was that MTA-exposed dendritic cells were worse at stimulating T cell responses.20PubMed Central. The Tumor Metabolite 5′-Deoxy-5’Methylthioadenosine (MTA) Inhibits Maturation and T Cell-Stimulating Capacity of Dendritic Cells This helps explain why MTAP-deleted tumors may be particularly adept at evading immune surveillance and why some patients with these tumors respond poorly to checkpoint immunotherapy on its own.
An experimental approach to reversing this immunosuppression involves directly degrading the excess MTA. Administration of a pharmacologically optimized, PEGylated version of the MTAP enzyme in mouse models normalized MTA levels in the tumor microenvironment and restored T cell function, producing strong anti-tumor effects that depended on CD8+ T cells. This enzyme therapy worked specifically in MTAP-deficient tumors and not in MTAP-intact ones.21Cancer Cell. MTAP deletion confers altered immunometabolism and tumors immune evasion
Combining Metabolic Targeting with Immunotherapy
Given that MTAP deletion both creates a synthetic lethal vulnerability and suppresses anti-tumor immunity, combining metabolic targeting with immune checkpoint therapy is a logical next step. Early preclinical work supports the idea. In mouse models of MTAP-loss tumors, combining an MTA-cooperative PRMT5 inhibitor (MRTX1719) with anti-PD-1 therapy produced superior anti-tumor activity compared to either treatment alone.22PubMed Central. MTA-cooperative PRMT5 inhibitors enhance T cell-mediated antitumor activity in MTAP-loss tumors The rationale is that the PRMT5 inhibitor attacks the tumor cell directly while also partially relieving the MTA-driven immunosuppression, making the tumor more visible to the immune system right as a checkpoint inhibitor removes another immune brake.
A separate line of investigation has looked at methionine metabolism from the dietary side. In MTAP-deleted osteosarcoma models, restricting dietary methionine or inhibiting MAT2A triggered immune-related signaling pathways in tumor cells, attracted CD8+ T cells into the tumor, and upregulated PD-L1 expression on the cancer cells. When this methionine intervention was combined with anti-PD-1 therapy, the combination provided a significant survival benefit compared to either approach alone.23PubMed Central. Methionine intervention induces PD-L1 expression to enhance the immune checkpoint therapy response in MTAP-deleted osteosarcoma The increased PD-L1 expression may seem counterintuitive since PD-L1 helps tumors hide from immune attack, but it actually sets the stage for PD-1/PD-L1 blocking antibodies to be more effective: the more PD-L1 a tumor expresses, the more there is for the drug to block.24Cell Reports Medicine. Methionine intervention enhances immune checkpoint therapy in MTAP-deleted osteosarcoma These are mouse studies and a long way from clinical practice, but they outline how metabolic rewiring in MTAP-deleted tumors could be turned into a two-pronged treatment strategy.
MTAP-Targeted Strategies in Blood Cancers
Although much recent attention has focused on solid tumors, the story of MTAP in cancer began in hematologic malignancies. T-cell ALL, in particular, has deletion rates around a third or higher.25Blood. Frequent deletion in the methylthioadenosine phosphorylase gene in T- cell acute lymphoblastic leukemia: strategies for enzyme-targeted therapy Early work showed that MTAP-deficient leukemia cells were exquisitely sensitive to methionine deprivation, losing viability within 48 hours, while normal lymphocytes were barely affected. This selectivity sparked interest in enzyme-targeted therapy using drugs that block purine synthesis, because MTAP-deleted cells lack the salvage pathway that would normally rescue them.
More recently, preclinical testing in patient-derived T-ALL xenograft models demonstrated that the combination of pralatrexate and 6-thioguanine was effective against MTAP-deficient leukemia, providing a rationale for using these agents together in MTAP-negative leukemias and lymphomas.26PubMed Central. Methylthioadenosine phosphorylase (MTAP)-deficient T-cell ALL xenografts are sensitive to pralatrexate and 6-thioguanine alone and in combination These older drug-based approaches and the newer PRMT5/MAT2A-directed strategies represent different generations of thinking about the same underlying vulnerability: the metabolic dead end that MTAP loss creates.
The Structural Chemistry Behind MTA-Cooperative Inhibitors
What makes MTA-cooperative PRMT5 inhibitors conceptually different from conventional enzyme inhibitors is that they don’t just block the enzyme — they exploit the altered biochemistry of MTAP-deleted cells. In a normal cell, SAM occupies the PRMT5 cofactor pocket and helps the enzyme do its job. In an MTAP-deleted cell, MTA competes with SAM for that pocket. MTA-cooperative inhibitors are designed to bind PRMT5 in the presence of MTA rather than SAM, which means they preferentially dock onto the version of PRMT5 that exists inside tumor cells. Crystal structure studies have shown that these compounds can extend into the SAM-binding region and form specific hydrogen bonds that increase selectivity for the MTA-bound form of the enzyme over the SAM-bound form.27Journal of Medicinal Chemistry. MTA-Cooperative PRMT5 Inhibitors: Mechanism Switching Through Structure-Based Design This elegant selectivity mechanism is what gives these drugs their wide therapeutic window: they hit tumor PRMT5 hard while largely leaving normal-tissue PRMT5 alone.
The compounds identified through DNA-encoded library screens, like AM-9934, take a slightly different structural approach by occupying the arginine substrate pocket of MTA-bound PRMT5 rather than competing at the SAM site, but the principle is the same — selectivity arises from the unique biochemical environment inside MTAP-deleted cells.8PubMed Central. MTA-cooperative PRMT5 inhibitors from cofactor-directed DNA-encoded library screens Multiple pharmaceutical groups are now pursuing variations on this theme, and the diversity of chemical starting points is a good sign for the field, because if one compound fails for reasons unrelated to the target biology, others built on different scaffolds can continue.
Where Clinical Development Stands
As of the most recent literature, MTA-cooperative PRMT5 inhibitors and MAT2A inhibitors are both advancing through clinical development for MTAP-deficient cancers.28American Society of Clinical Oncology Educational Book. Novel Synthetic Lethal Therapeutic Strategies in Precision Oncology Preclinical data on MAT2A inhibitors such as AG-270 and IDE397 showed that while these drugs reduced SAM levels regardless of MTAP status, the downstream effects on PRMT5 activity and tumor growth were preferentially stronger in MTAP-null tumor models across multiple cancer types including lung, pancreatic, and bladder cancers. This selective synthetic lethality in MTAP-deleted tumors is what justifies using MTAP status as a patient selection biomarker in trials.
One practical challenge for clinical development is ensuring that diagnostic testing can reliably identify the right patients. The discussion above on IHC, NGS, and liquid biopsy methods matters directly here. Trials need companion diagnostics that are fast, accurate, and widely available. The emerging consensus is that IHC is a cost-effective first-line screen, NGS provides definitive genomic confirmation, and liquid biopsy may serve patients who cannot undergo tissue biopsy or need rapid screening. The concordance data between these methods is reassuring but imperfect enough that combining approaches will likely be standard practice for enrollment in precision trials.
The field is also grappling with potential resistance. When a drug kills most of a tumor’s cells but a few survive, those survivors often have adaptations that render the drug less effective over time. For MTAP-targeted therapies, the resistance landscape is still being mapped, but the availability of two distinct target classes (PRMT5 and MAT2A) and the potential to combine metabolic targeting with immunotherapy provide options for sequencing or combining treatments to stay ahead of resistance. Whether this promise holds up in patients, rather than in mice, remains the central open question for the next several years of clinical investigation.